Overview of the 3rd isirv‐Antiviral Group Conference – advances in clinical management

Influenza and Other Respiratory Viruses

Aeron C. Hurt¹  David S. Hui³  Alan Hay² 

[1] WHO Collaborating Centre for Reference and Research on Influenza, VIDRL at the Peter Doherty Institute for Infection and Immunity, Parkville, Vic., Australia;National Institute for Medical Research, Mill Hill, London, UK;Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong

关键词: Antivirals;    clinical management;    immunocompromised;    influenza;    respiratory;    treatment;   

DOI  :  10.1111/irv.12293

来源: Wiley

【 摘 要 】

Abstract

This review highlights the main points which emerged from the presentations and discussions at the 3rd isirv-Antiviral Group Conference - advances in clinical management. The conference covered emerging and potentially pandemic influenza viruses and discussed novel/pre-licensure therapeutics and currently approved antivirals and vaccines for the control of influenza. Current data on approved and novel treatments for non-influenza respiratory viruses such as MERS-CoV, respiratory syncytial virus (RSV) and rhinoviruses and the challenges of treating immunocompromised patients with respiratory infections was highlighted.

【 授权许可】

CC BY   
© 2014 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.